Annexin Pharmaceuticals AB Logo

Annexin Pharmaceuticals AB

ANNX | ST

Overview

Corporate Details

ISIN(s):
SE0009664154
LEI:
5493000JP703HGPJEX27
Country:
Sweden
Address:
KAMMAKARGATAN 48, 111 60 Stockholm
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on developing therapies centered on the human protein Annexin A5. The company's lead drug candidate, ANXV, is a recombinant form of Annexin A5 designed to target the lipid phosphatidylserine (PS), which is exposed on the surface of stressed and damaged cells. By binding to PS, ANXV aims to create a protective shield that counteracts cellular stress, modulates immune responses, and repairs tissue injury. The company is primarily investigating ANXV's therapeutic potential in ophthalmology, specifically for Retinal Vein Occlusion (RVO), where it is positioned as a potential First-in-Class treatment, and in oncology. The drug's unique mechanism of action offers a novel approach for various diseases where PS exposure is a contributing factor.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Annexin Pharmaceuticals AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Initiator Pharma A/S Logo
Clinical-stage firm developing drugs for nervous system disorders like ED & trigeminal neuralgia.
Denmark INIT
Innate Pharma Logo
Clinical-stage biotech developing antibodies that harness NK cells to fight cancer.
France IPH
IntegraGen Logo
Genomics specialist providing analyses & SaaS for cancer/rare diseases to researchers & labs.
France ALINT
Inventiva Logo
Develops oral small molecule therapies for fibrosis, oncology, and lysosomal storage disorders.
France IVA
IRLAB Therapeutics Logo
Developing novel treatments for neurodegenerative conditions like Parkinson's disease.
Sweden IRLAB
Isofol Medical Logo
Clinical-stage biotech developing a drug to enhance chemotherapy efficacy for colorectal cancer.
Sweden ISOFOL
IXICO PLC Logo
AI-powered neuroimaging and biomarker analytics for neurological clinical trials.
United Kingdom IXI
J. Molner AS Logo
A CDRO specializing in generic injectable and topical drugs for the North American market.
Estonia JML
Kadimastem Ltd. Logo
Develops off-the-shelf cell therapies for neurodegenerative and metabolic diseases.
Israel KDST
Kancera Logo
Develops drugs targeting the fractalkine axis for severe inflammation and resistant cancers.
Sweden KAN